Background The prognosis for adults with relapsed acute lymphoblastic leukemia is poor.
We sought to determine whether inotuzumab ozogamicin, an anti-CD22 antibody conjugated …

Purpose Blinatumomab, a bispecific single-chain antibody targeting the CD19 antigen, is a
member of a novel class of antibodies that redirect T cells for selective lysis of tumor cells. In …

Background Reduced-intensity conditioning regimens have been developed to minimise
early toxic effects and deaths after allogeneic haemopoietic cell transplantation. However, the …

Purpose The majority of patients with acute myeloid leukemia (AML) who achieve complete
remission (CR) relapse with conventional postremission chemotherapy. Allogeneic stem-cell …

Background Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality
after allogeneic haematopoietic cell transplantation from unrelated donors. Anti-T-cell …

PURPOSE Despite undergoing allogeneic hematopoietic stem cell transplantation (HCT),
patients with acute myeloid leukemia (AML) with internal tandem duplication mutation in the …

T cell–engaging CD19/CD3-bispecific BiTE Ab blinatumomab has shown an 80% complete
molecular response rate and prolonged leukemia-free survival in patients with minimal …

Purpose Patients with relapsed or refractory acute lymphoblastic leukemia (ALL) have a dismal
prognosis. CD19 is homogenously expressed in B-precursor ALL and can be targeted by …

Persistence or recurrence of minimal residual disease (MRD) after chemotherapy results in
clinical relapse in patients with acute lymphoblastic leukemia (ALL). In a phase 2 trial of B-…

Despite improvements in first-line therapies, published results on the treatment of relapsed
adult acute lymphoblastic leukemia (ALL) show that prognosis is still poor. The aim of the …